RPC to Exhibit Onko-Sure® Cancer Test at the ASCO Annual Meeting
Product News May 20, 2011
Radient Pharmaceuticals Corporation, has announced the Company will exhibit its FDA-cleared Onko-Sure® cancer test at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-6, 2011. RPC will be located at booth 3101 in the exhibition hall.
ASCO's 2010 Annual Meeting had a total of 32,700 attendees, including 26,600 members of the worldwide oncology community. As with last year's ASCO Meeting, it is expected that this year's ASCO Meeting will consist of educational and scientific sessions that offer cutting-edge information on the diagnosis and treatment of patients with cancer. RPC's Onko-Sure® cancer test kit is cleared by the FDA for colo-rectal cancer treatment and recurrence monitoring.
ASCO is the world's leading professional organization representing physicians of all oncology subspecialties who care for people with cancer. With nearly 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO's overarching goal is improving cancer care and prevention.
RPC's Director of Oncology, Dr. Afsaneh Motamed-Khorasani and Mr. Christopher Gee, Director of International Sales & Marketing, will be participating and exhibiting at the Meeting.
"Participating in ASCO 2011 is another step forward in increasing awareness of Onko-Sure® through outreach to key opinion leaders on a national and international level. Providing published clinical study results and our product's strengths at scientific conferences is a key component of building adoption rates for Onko-Sure® globally," stated RPC's Director of Oncology, Dr. Motamed-Khorasani.
Mr. Douglas MacLellan, RPC's CEO, added, "As a cancer test that is in use and cleared to market in numerous territories across the world, we benefit from presenting Onko-Sure® to the international cancer care and research community attending ASCO. By having our science and marketing executives available at the event we seek to have meaningful discussions with physicians, medical oncologists, cancer advocacy groups, and healthcare professionals involved in cancer research and testing. It's also a great opportunity to build relationships with new healthcare and lab partners internationally."
This is the 3rd scientific conference attended by RPC in 2011. The Company plans to increase its presence at national and international conferences in the future.
In January, RPC presented Onko-Sure® at the BIO Asia Partnering Conference in Tokyo. In February, RPC provided a poster presentation featuring lung cancer study results at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO) in Lugano, Switzerland.